Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

PTGEF is undervalued big time. BHVN surged again.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ronpopeil Member Profile
 
Followed By 117
Posts 9,382
Boards Moderated 0
Alias Born 10/05/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:34:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:29:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:27:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:27:00 PM
Biohaven, Artizan to work on Parkinson's drug discovery program Seeking Alpha - 11/18/2021 8:23:52 AM
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease GlobeNewswire Inc. - 11/18/2021 7:30:00 AM
Biohaven's migraine med Nurtec approved in Kuwait Seeking Alpha - 11/17/2021 7:10:54 AM
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine PR Newswire (US) - 11/17/2021 6:57:00 AM
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital PR Newswire (US) - 11/15/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/10/2021 6:19:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:29:29 PM
Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout Seeking Alpha - 11/9/2021 9:06:59 AM
Biohaven, Pfizer in Collaboration to Commercialize Rimegepant Dow Jones News - 11/9/2021 8:47:00 AM
Biohaven Pharmaceuticals EPS beats by $0.11, beats on revenue Seeking Alpha - 11/9/2021 8:33:16 AM
Pfizer to gains ex-U.S. rights to Biohaven migraine med Nurtec in up to $1.24B deal Seeking Alpha - 11/9/2021 8:13:16 AM
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States PR Newswire (US) - 11/9/2021 7:46:00 AM
Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments PR Newswire (US) - 11/9/2021 7:45:00 AM
Biohaven Pharmaceuticals Q3 2021 Earnings Preview Seeking Alpha - 11/8/2021 11:47:53 AM
Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021 PR Newswire (US) - 11/4/2021 7:30:00 AM
Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway PR Newswire (US) - 11/2/2021 7:30:00 AM
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma PR Newswire (US) - 10/27/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/6/2021 7:01:35 AM
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment PR Newswire (US) - 10/5/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/1/2021 5:11:13 PM
Biohaven Pharmaceutical, ASLAN Pharmaceuticals among major healthcare premarket losers' pack Seeking Alpha - 9/27/2021 8:15:35 AM
ronpopeil   Wednesday, 05/10/17 04:09:16 PM
Re: nohypeneeded post# 2
Post # of 21 
PTGEF is undervalued big time. BHVN surged again. PTGEF should be much higher based on their 6+ million share ownership of BHVN. That doesn't even factor in their ownership in other promising companies

"Don't worry about the world coming to an end today. It's already tomorrow in Australia"

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences